Mayne Pharma Group Limited (MYX.AX)
AUD 6.98
(-0.29%)
AUD 6.98
(-0.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -45.85 Million AUD | 75.4% |
| 2023 | -186.44 Million AUD | -52.97% |
| 2022 | -121.87 Million AUD | -9041.97% |
| 2021 | 1.36 Million AUD | 111.24% |
| 2020 | -12.13 Million AUD | -141.58% |
| 2019 | 29.17 Million AUD | -21.41% |
| 2018 | 37.12 Million AUD | -69.64% |
| 2017 | 122.26 Million AUD | 120.29% |
| 2016 | 55.5 Million AUD | 222.91% |
| 2015 | 17.18 Million AUD | -46.9% |
| 2014 | 32.37 Million AUD | 441.68% |
| 2013 | 5.97 Million AUD | 136.02% |
| 2012 | 2.53 Million AUD | 409.91% |
| 2011 | -817 Thousand AUD | -200.38% |
| 2010 | 813.88 Thousand AUD | 115.76% |
| 2009 | -5.16 Million AUD | -22.04% |
| 2008 | -4.23 Million AUD | -115.47% |
| 2007 | -1.96 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q4 | -7.25 Million AUD | 0.0% |
| 2024 Q2 | -38.83 Million AUD | 0.0% |
| 2024 FY | -77.83 Million AUD | 58.25% |
| 2023 FY | -186.44 Million AUD | -52.97% |
| 2023 Q2 | -122.26 Million AUD | 0.0% |
| 2023 Q4 | -64.18 Million AUD | 0.0% |
| 2022 Q2 | -24.25 Million AUD | 0.0% |
| 2022 FY | -121.87 Million AUD | -9041.97% |
| 2022 Q4 | -38.11 Million AUD | 0.0% |
| 2021 Q2 | 434 Thousand AUD | 0.0% |
| 2021 Q4 | 929 Thousand AUD | 0.0% |
| 2021 FY | 1.36 Million AUD | 111.24% |
| 2020 FY | -12.13 Million AUD | -141.58% |
| 2020 Q2 | -6.87 Million AUD | 0.0% |
| 2020 Q4 | -5.25 Million AUD | 0.0% |
| 2019 Q4 | -4.66 Million AUD | 0.0% |
| 2019 FY | 29.17 Million AUD | -21.41% |
| 2019 Q2 | 23.19 Million AUD | 0.0% |
| 2018 Q2 | -5.75 Million AUD | 0.0% |
| 2018 FY | 37.12 Million AUD | -69.64% |
| 2018 Q4 | 70.45 Million AUD | 0.0% |
| 2017 Q2 | 69.77 Million AUD | 0.0% |
| 2017 Q4 | 47.22 Million AUD | 0.0% |
| 2017 FY | 122.26 Million AUD | 120.29% |
| 2016 FY | 55.5 Million AUD | 222.91% |
| 2016 Q4 | 25.21 Million AUD | 0.0% |
| 2016 Q2 | 20.62 Million AUD | 0.0% |
| 2015 Q4 | 8.5 Million AUD | 0.0% |
| 2015 Q2 | 6.92 Million AUD | 0.0% |
| 2015 FY | 17.18 Million AUD | -46.9% |
| 2014 Q2 | 13.66 Million AUD | 0.0% |
| 2014 FY | 32.37 Million AUD | 441.68% |
| 2014 Q4 | 17.12 Million AUD | 0.0% |
| 2013 Q4 | 7.87 Million AUD | 227.64% |
| 2013 Q3 | 2.4 Million AUD | -38.6% |
| 2013 Q2 | 3.91 Million AUD | 0.0% |
| 2013 FY | 5.97 Million AUD | 136.02% |
| 2012 Q2 | 1.07 Million AUD | 415.79% |
| 2012 Q3 | 1.07 Million AUD | 0.0% |
| 2012 Q4 | 1.07 Million AUD | 0.0% |
| 2012 FY | 2.53 Million AUD | 409.91% |
| 2012 Q1 | 209 Thousand AUD | 0.0% |
| 2011 Q4 | 209 Thousand AUD | 0.0% |
| 2011 FY | -817 Thousand AUD | -200.38% |
| 2011 Q3 | 209 Thousand AUD | 0.0% |
| 2011 Q2 | 209 Thousand AUD | 2.72% |
| 2011 Q1 | 203.47 Thousand AUD | 0.0% |
| 2010 Q3 | 203.47 Thousand AUD | 0.0% |
| 2010 Q4 | 203.47 Thousand AUD | 0.0% |
| 2010 Q1 | -1.29 Million AUD | 0.0% |
| 2010 Q2 | 203.47 Thousand AUD | 115.76% |
| 2010 FY | 813.88 Thousand AUD | 115.76% |
| 2009 Q3 | -1.29 Million AUD | 0.0% |
| 2009 Q2 | -1.29 Million AUD | -22.04% |
| 2009 Q1 | -1.05 Million AUD | 0.0% |
| 2009 Q4 | -1.29 Million AUD | 0.0% |
| 2009 FY | -5.16 Million AUD | -22.04% |
| 2008 Q1 | -491.02 Thousand AUD | 0.0% |
| 2008 Q4 | -1.05 Million AUD | 0.0% |
| 2008 Q2 | -1.05 Million AUD | -115.47% |
| 2008 Q3 | -1.05 Million AUD | 0.0% |
| 2008 FY | -4.23 Million AUD | -115.47% |
| 2007 FY | -1.96 Million AUD | 0.0% |
| 2007 Q4 | -491.02 Thousand AUD | 0.0% |
| 2007 Q3 | -491.02 Thousand AUD | 0.0% |
| 2007 Q2 | -491.02 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Firebrick Pharma Limited | -944.05 Thousand AUD | -4757.344% |